In previous work, we were able to show the generation of effective CD33-targeting CAR-NK cells for the treatment of acute myeloid leukemia (AML) [18], a disease for which no CAR-T cell therapy is available yet, and which demonstrates dismal overall survival rates especially for elderly patients [19, 20]. This evidence concerns the gene CD33 and acute myeloid leukemia.